Valeant bids $296M on Dendreon; AstraZeneca pairs with MD Anderson;

@FierceBiotech: Obama wants $215M to kick off 'precision medicine' project. More | Follow @FierceBiotech

@JohnCFierce: $ICPT up 38% this a.m., which is nuts. Article | Follow @JohnCFierce

@DamianFierce: The to-my-knowledge guest list for tomorrow's White House precision medicine thing: $FMI, $VRTX, $MRK, $REGN. | Follow @DamianFierce

> AstraZeneca ($AZN) signed a deal with the University of Texas' MD Anderson Cancer Center to team up on gynecologic malignancies, part of the center's Moon Shots R&D program. More

> Valeant Pharmaceuticals ($VRX) has signed a deal to acquire Dendreon ($DNDN), on the verge of bankruptcy, for $296 million. Story

> Three months after firing CEO Chris Viehbacher, Sanofi ($SNY) has yet to find a replacement, creating an embarrassing situation for the company as it prepares to present its 2014 results. News

Medical Device News

@FierceMedDev: Stomach-draining obesity startup gets $12M in debt to support PMA in mid-2015. More | Follow @FierceMedDev

@EmilyWFierce: Roche and Qualcomm join forces for next-gen remote patient monitoring system. Story | Follow @EmilyWFierce

> Wall Street buys into third med tech IPO of the week: Avinger. More

> J&J to distribute Insuline diabetes device in Russia to stem flagging diabetes care sales. News

> China medical device market to top Japan to claim No. 2 spot globally. Report

Pharma News

@FiercePharma: European regulators chart record year for new animal health products. More | Follow @FiercePharma

@EricPFierce: GSK is moving forward with its new API plant in Scotland. Story | Follow @EricPFierce

> Study of all data on Roche's highly debated Tamiflu says it does help. More

> Viehbacher's ouster, severance raise red flags for CEO candidates. News

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.